🇺🇸 FDA
Pipeline program

Anti-CD19 UCAR-T cells

PBC081

Phase 1 small_molecule active

Quick answer

Anti-CD19 UCAR-T cells for Dermatomyositis, Juvenile is a Phase 1 program (small_molecule) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
PRECISION BIOSCIENCES INC
Indication
Dermatomyositis, Juvenile
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials